P082 PREOPERATIVE ANTI-TNFS ARE ASSOCIATED WITH A SHORTER INTERVAL TO DE NOVO CROHN’S DISEASE AFTER ILEAL POUCH-ANAL ANASTOMOSIS FOR ULCERATIVE COLITIS

Anti-tumor necrosis factor (anti-TNF) agents are widely used in the treatment of moderate to severe ulcerative colitis (UC) since commercial approval in 1998. Many patients however ultimately require surgery with ileal pouch-anal anastomosis (IPAA). Conversion of UC to Crohn’s disease (CD) following IPAA is a devastating complication termed de novo Crohn’s disease (DNCD). Despite increasing adoption, few prior studies have evaluated the effect...